

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

**POLL RESULTS OF
THE 2022 SECOND EXTRAORDINARY GENERAL MEETING
HELD ON NOVEMBER 4, 2022**

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) announces that, at the 2022 second extraordinary general meeting of the Company (the “**EGM**”) held at 2:30 p.m. on Friday, November 4, 2022 at Ballroom, 2/F, L’Hermitage Hotel, 3031 Nanhai Boulevard, Nanshan District, Shenzhen, the PRC, all the proposed resolutions set out in the notice of the EGM were passed by way of poll. For details of the resolutions considered at the EGM, the Shareholders may refer to the notice of the EGM dated October 3, 2022 and the circular of the EGM dated October 3, 2022 of the Company (the “**Circular**”). Unless otherwise defined in this announcement, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the date of the EGM, the total number of Shares in issue is 1,467,296,204 Shares (including 1,247,201,704 A Shares and 220,094,500 H Shares). No Shareholder was required to abstain from voting on the resolutions under the Listing Rules. There was no Share entitling the holder to attend the meeting and abstain from voting in favour of the resolutions under Rule 13.40 of the Listing Rules. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the EGM. Tricor Investor Services Limited, the H Share registrar of the Company, acted as the scrutineer for vote-taking in respect of the H Shares at the EGM. The convening of the EGM was in compliance with the Company Law of the People’s Republic of China and the Articles.

The executive directors of the Company: Mr. Li Li, Ms. Li Tan and Mr. Shan Yu; and the independent non-executive directors of the Company: Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui, attended the EGM in person or by electronic means.

I. CONVENING OF THE MEETING

The total number of Shares entitling the holders to attend and vote on the resolutions at the EGM was 1,467,296,204 Shares (including 1,247,201,704 A Shares and 220,094,500 H Shares). The total number of Shares with voting rights represented by the Shareholders attending the EGM in person or by proxy was 1,009,852,900 Shares (including 987,245,374 A Shares and 22,607,526 H Shares), representing approximately 68.824% of the total number of Shares.

II. POLL RESULTS OF THE EGM

The poll results in respect of the respective resolutions at the EGM are set out below:

NO.	SPECIAL RESOLUTION (Resolution adopting non-consolidative voting)	NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
1	The resolution regarding the proposed issuance of corporate bonds.	1,005,839,800 99.603%	4,013,100 0.397%	0 0%
NO.	ORDINARY RESOLUTION (Resolution adopting non-consolidative voting)	NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
2	The resolution regarding the proposed change in use of proceeds.	1,005,839,800 99.603%	4,013,100 0.397%	0 0%

As more than two-third of the votes from the Shareholders (including their proxies) attending the EGM were cast in favour of the resolution numbered 1, the resolution was duly passed as special resolution.

As more than half of the votes from the Shareholders (including their proxies) attending the EGM were cast in favour of the resolution numbered 2, the resolution was duly passed as ordinary resolution.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
November 4, 2022

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan and Mr. Shan Yu; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.